PharmGenScience Signs Technology Transfer Agreement With Immunoposage For One-Month Long-Term Obesity Treatment
Feb 03, 2025
FarmGenScience (CEO Park Hee-deok, Kim Hye-yeon) announced on the 3rd that it signed a technology transfer agreement with Immunofozie (CEO Ahn Sung-min, Jang Ki-ho) to develop a treatment for obesity
Through this contract, FarmGenScience plans to develop a one-month long-lasting GLP-1 analogue that shows excellent obesity treatment effects by utilizing Immunofozi's proprietary Elastin-Like Polypeptide (ELP) platform technology and BBB linker technology that can pass through the Blood-Brain Barrier (BBB).
Immunofozie's ELP platform is a technology that enables the continuous release of protein or peptide-based drugs in the body due to its unique temperature sensitivity and self-assembly properties.
GLP-1 (Glucagon-Like Peptide-1) analogs are currently important drugs in the treatment of obesity and diabetes, and are known to be effective in weight loss and blood sugar control, and existing GLP-1 analogs have been developed as injection formulations once a day or once a week due to their short duration of effectiveness after administration. The obesity treatment regimen approved in Korea in 2024 is also a once a week formulation.
A PalmGen Science official said "We expect this technology transfer to significantly improve the convenience of taking medication compared to existing obesity treatments with once a month treatment, thereby improving the quality of life.""The BBB-permeable long-term persistent GLP-1 analogue of Immunofozie represents an important step forward in the treatment of obesity, and we are confident that we will be able to secure competitiveness in the domestic and global obesity treatment markets in the future."
In addition, "This contract will be an important opportunity to further strengthen FarmGenScience's R&D capabilities and further solidify its potential for the development of next-generation obesity treatments."
With this technology transfer contract, FarmGenScience emphasized that it will secure a new obesity treatment pipeline and continue to actively expand Open Innovation with domestic and foreign companies through cooperation with Immunofozie.
Through this contract, FarmGenScience plans to develop a one-month long-lasting GLP-1 analogue that shows excellent obesity treatment effects by utilizing Immunofozi's proprietary Elastin-Like Polypeptide (ELP) platform technology and BBB linker technology that can pass through the Blood-Brain Barrier (BBB).
Immunofozie's ELP platform is a technology that enables the continuous release of protein or peptide-based drugs in the body due to its unique temperature sensitivity and self-assembly properties.
GLP-1 (Glucagon-Like Peptide-1) analogs are currently important drugs in the treatment of obesity and diabetes, and are known to be effective in weight loss and blood sugar control, and existing GLP-1 analogs have been developed as injection formulations once a day or once a week due to their short duration of effectiveness after administration. The obesity treatment regimen approved in Korea in 2024 is also a once a week formulation.
A PalmGen Science official said "We expect this technology transfer to significantly improve the convenience of taking medication compared to existing obesity treatments with once a month treatment, thereby improving the quality of life.""The BBB-permeable long-term persistent GLP-1 analogue of Immunofozie represents an important step forward in the treatment of obesity, and we are confident that we will be able to secure competitiveness in the domestic and global obesity treatment markets in the future."
In addition, "This contract will be an important opportunity to further strengthen FarmGenScience's R&D capabilities and further solidify its potential for the development of next-generation obesity treatments."
With this technology transfer contract, FarmGenScience emphasized that it will secure a new obesity treatment pipeline and continue to actively expand Open Innovation with domestic and foreign companies through cooperation with Immunofozie.
|
This article was translated by Naver AI translator.
